María T. Abreu

33.3k total citations · 9 hit papers
378 papers, 21.4k citations indexed

About

María T. Abreu is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, María T. Abreu has authored 378 papers receiving a total of 21.4k indexed citations (citations by other indexed papers that have themselves been cited), including 245 papers in Genetics, 158 papers in Epidemiology and 114 papers in Immunology. Recurrent topics in María T. Abreu's work include Inflammatory Bowel Disease (233 papers), Microscopic Colitis (145 papers) and Helicobacter pylori-related gastroenterology studies (47 papers). María T. Abreu is often cited by papers focused on Inflammatory Bowel Disease (233 papers), Microscopic Colitis (145 papers) and Helicobacter pylori-related gastroenterology studies (47 papers). María T. Abreu collaborates with scholars based in United States, Canada and Italy. María T. Abreu's co-authors include Masayuki Fukata, Moshe Arditi, Lisa Thomas, Stephan R. Targan, William J. Sandborn, Eric A. Vasiliauskas, Marla C. Dubinsky, Russell D. Cohen, Gary R. Lichtenstein and William J. Tremaine and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

María T. Abreu

348 papers receiving 21.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

2021 1.5k citations William J. Sandborn, Bruce E. Sands et al. Gastroenterology profile →
Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function

2010 954 citations María T. Abreu profile →
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

2019 787 citations Bruce E. Sands, William J. Sandborn et al. profile →
Decreased Expression of Toll-Like Receptor-4 and MD-2 Correlates with Intestinal Epithelial Cell Protection Against Dysregulated Proinflammatory Gene Expression in Response to Bacterial Lipopolysaccharide

2001 569 citations María T. Abreu et al. profile →
Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors

2007 522 citations Masayuki Fukata, Anli Chen et al. Gastroenterology profile →
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

2011 441 citations María T. Abreu, Brian G. Feagan et al. profile →
Diet as a Trigger or Therapy for Inflammatory Bowel Diseases

2016 289 citations María T. Abreu et al. Gastroenterology profile →
Epithelial Toll-like receptors and their role in gut homeostasis and disease

2020 281 citations Juan F. Burgueño, María T. Abreu profile →
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

2024 42 citations María T. Abreu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
María T. Abreu United States	76	10.1k	7.3k	6.4k	5.0k	4.8k	378	21.4k
Marc Ferrante Belgium	64	12.4k 1.2×	8.9k 1.2×	4.7k 0.7×	5.3k 1.1×	4.6k 1.0×	543	21.4k
Gerhard Rogler Switzerland	76	11.0k 1.1×	7.6k 1.0×	5.6k 0.9×	6.9k 1.4×	7.7k 1.6×	645	26.9k
Toshifumi Hibi∥ Japan	81	9.9k 1.0×	8.3k 1.1×	7.1k 1.1×	7.6k 1.5×	5.3k 1.1×	788	26.6k
Sander J. H. van Deventer Netherlands	72	7.7k 0.8×	7.7k 1.1×	7.3k 1.1×	4.9k 1.0×	4.0k 0.8×	269	22.1k
Eduard F. Stange Germany	64	8.3k 0.8×	6.0k 0.8×	3.6k 0.6×	5.4k 1.1×	5.1k 1.1×	300	18.4k
Laurent Beaugerie France	61	11.1k 1.1×	8.7k 1.2×	2.5k 0.4×	5.2k 1.0×	3.6k 0.8×	299	18.1k
Subrata Ghosh United Kingdom	81	17.1k 1.7×	12.2k 1.7×	5.9k 0.9×	8.5k 1.7×	5.1k 1.1×	590	31.0k
Antoine Cortot France	62	11.7k 1.2×	8.3k 1.1×	4.7k 0.7×	6.0k 1.2×	3.2k 0.7×	275	19.3k
Stephan R. Targan United States	90	18.3k 1.8×	12.5k 1.7×	11.5k 1.8×	6.0k 1.2×	4.4k 0.9×	434	31.0k
Julián Panés Spain	84	14.2k 1.4×	11.2k 1.5×	4.8k 0.8×	8.5k 1.7×	2.8k 0.6×	590	26.0k

Countries citing papers authored by María T. Abreu

Since Specialization

Citations

This map shows the geographic impact of María T. Abreu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María T. Abreu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María T. Abreu more than expected).

Fields of papers citing papers by María T. Abreu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María T. Abreu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María T. Abreu. The network helps show where María T. Abreu may publish in the future.

Co-authorship network of co-authors of María T. Abreu

This figure shows the co-authorship network connecting the top 25 collaborators of María T. Abreu. A scholar is included among the top collaborators of María T. Abreu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María T. Abreu. María T. Abreu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Feagan, B G, Maia Kayal, Stefan Schreiber, et al.. (2025). P1183 Multivariable analysis of baseline variables associated with efficacy outcomes in the ELEVATE UC clinical programme. Journal of Crohn s and Colitis. 19(Supplement_1). i2149–i2150.

Chi, Xiaofei, Matthew J. Gurka, Jaclyn Hall, et al.. (2024). Healthcare Utilization and Geographic Distribution of Advanced Therapy in Minority Race and Ethnic Groups With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 31(2). 344–350.

Vincenzo, Federica Di, et al.. (2024). Gender Inequity in Pharma-Supported Inflammatory Bowel Disease Presentations: Shining a Light on Opportunities for Equality and Transparency in Medical Research. Gastroenterology. 167(7). 1256–1259.e2. 2 indexed citations

Ghosh, Subrata, Brian G. Feagan, Elyssa Ott, et al.. (2024). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis. Journal of Crohn s and Colitis. 18(7). 1091–1101. 17 indexed citations

Ducasa, Gloria Michelle, Ana M. Santander, Nivis Brito, et al.. (2023). Intestinal Epithelial Inactivity of Dual Oxidase 2 Results in Microbiome-Mediated Metabolic Syndrome. Cellular and Molecular Gastroenterology and Hepatology. 16(4). 557–572. 6 indexed citations

Danese, Silvio, et al.. (2023). DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. Journal of Crohn s and Colitis. 17(Supplement_1). i101–i102. 4 indexed citations

Ducasa, Gloria Michelle, Nivis Brito, Ana M. Santander, et al.. (2023). LOSS OF EPITHELIAL DUOX2 SIGNALING IS ACCOMPANIED BY A REDUCTION IN AKKERMANSIACEAE AND PROMOTES THE DEVELOPMENT OF METABOLIC SYNDROME IN A MICROBIOME-DEPENDENT MANNER. Inflammatory Bowel Diseases. 29(Supplement_1). S72–S72. 2 indexed citations

Danese, Silvio, Waqqas Afif, María T. Abreu, et al.. (2023). OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension. Journal of Crohn s and Colitis. 17(Supplement_1). i19–i20. 2 indexed citations

Abreu, María T., Silvio Danese, Douglas C. Wolf, et al.. (2023). 950 LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION. Gastroenterology. 164(6). S–208. 1 indexed citations

10.

Danese, Silvio, et al.. (2023). P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis. Journal of Crohn s and Colitis. 17(Supplement_1). i591–i593. 2 indexed citations

11.

Abreu, María T., et al.. (2022). Genetic counseling and carrier screening in candidates for gamete donation at a Portuguese center. JBRA. 27(2). 180–184. 2 indexed citations

12.

Yarur, Andrés, Vikram Kanagala, Dan J. Stein, et al.. (2017). Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. 45(7). 933–940. 210 indexed citations

13.

Koru‐Sengul, Tulay, Feng Miao, Olveen Carrasquillo, et al.. (2016). Colorectal Tumors From Different Racial and Ethnic Minorities Have Similar Rates of Mismatch Repair Deficiency. Clinical Gastroenterology and Hepatology. 14(8). 1163–1171. 22 indexed citations

14.

Davies, Julie, Rebeca Santaolalla, Richard J. von Furstenberg, Susan Henning, & María T. Abreu. (2015). The Viral Mimetic Polyinosinic:Polycytidylic Acid Alters the Growth Characteristics of Small Intestinal and Colonic Crypt Cultures. PLoS ONE. 10(9). e0138531–e0138531. 18 indexed citations

15.

Yarur, Andrés, et al.. (2014). The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Alimentary Pharmacology & Therapeutics. 39(8). 802–810. 121 indexed citations

16.

Talley, Nicholas J., María T. Abreu, Jean-Paul Achkar, et al.. (2011). An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease. The American Journal of Gastroenterology. 106. S2–S25. 229 indexed citations

17.

Khan, Khurram J, Thomas Ullman, Alexander C. Ford, et al.. (2011). Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 106(4). 661–673. 382 indexed citations

18.

Liu, Weicheng, Xinshou Ouyang, Jianjun Yang, et al.. (2009). AP-1 Activated by Toll-like Receptors Regulates Expression of IL-23 p19. Journal of Biological Chemistry. 284(36). 24006–24016. 110 indexed citations

19.

Fukata, Masayuki, Anli Chen, Arunan S. Vamadevan, et al.. (2007). Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors. Gastroenterology. 133(6). 1869–1869.e14. 522 indexed citations breakdown →

20.

Brown, Steven J & María T. Abreu. (2005). Biologic therapies in inflammatory bowel disease. 29(7). 38–63. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact